Literature DB >> 33750983

IL-6 and IL-10 in the serum and exfoliated cervical cells of patients infected with high-risk human papillomavirus.

Camila Mareti Bonin-Jacob1,2, Larissa Zatorre Almeida-Lugo1, Marco Antonio Moreira Puga1, Ana Paula Machado3, Cacilda Tezelli Junqueira Padovani2, Mariana Calarge Noceti2, Alda Maria Teixeira Ferreira2, Carlos Eurico Dos Santos Fernandes2, Júlio César Possati Resende4, Adriane Cristina Bovo5, Inês Aparecida Tozetti3.   

Abstract

Persistent infection by high-risk human papillomavirus (HR-HPV) is the main cause of cervical cancer and its precursor lesions. While some cytokines help immune cells in virus clearance, others contribute to the persistence of infection and neoplastic progression. Here, the levels of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-10, IL-6, IL-4, and IL-2 were quantified in the serum and exfoliated cervical cells (ECCs) of patients with HR-HPV, and the presence of IL-6+ cells was investigated in uterine cervix biopsies. Cytokine levels in the serum and ECCs of 26 HR-HPV DNA-positive patients and 18 HPV DNA-negative patients were measured using flow cytometry. Fifteen uterine cervix biopsy samples embedded in paraffin were subjected to immunohistochemical analysis for the detection of IL-6+ cells. HR-HPV-positive patients showed increased IL-6 and IL-10 in the ECCs and serum, respectively. Compared with HPV DNA-positive patients, HPV DNA-negative patients had higher levels of IL-6 in ECCs. Patients with multiple infections of HPV had higher levels of IL-6 in their ECCs than those with a single infection. Immunostaining of uterine cervix biopsy samples revealed no differences in IL-6 expression between the different classes of histopathological lesions. However, differences were observed in the expression levels of IL-6 and IL-10 at the systemic and local levels in HR-HPV-positive patients without cervical lesions. Considering the functional characteristics of these cytokines, it can be inferred that such patients are prone to persistent HPV infection.

Entities:  

Year:  2021        PMID: 33750983      PMCID: PMC7984643          DOI: 10.1371/journal.pone.0248639

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  42 in total

1.  IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells.

Authors:  M Okada; M Kitahara; S Kishimoto; T Matsuda; T Hirano; T Kishimoto
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

2.  Interleukin-17 expression in the serum and exfoliated cervical cells of patients infected with high-risk oncogenic human papillomavirus.

Authors:  Camila Mareti Bonin; Larissa Zatorre Almeida-Lugo; Andrielli Rodrigues Dos Santos; Cacilda Tezelli Junqueira Padovani; Ana Flávia Silva Pina; Alda Maria Teixeira Ferreira; Carlos Eurico Dos Santos Fernandes; Júlio César Possati Resende; Adriane Cristina Bovo; Inês Aparecida Tozetti
Journal:  Cytokine       Date:  2019-05-01       Impact factor: 3.861

3.  Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro.

Authors:  D Eustace; X Han; R Gooding; A Rowbottom; P Riches; E Heyderman
Journal:  Gynecol Oncol       Date:  1993-07       Impact factor: 5.482

4.  Determination of cytokine protein levels in cervical mucus samples from young women by a multiplex immunoassay method and assessment of correlates.

Authors:  Jay A Lieberman; Anna-Barbara Moscicki; Jan L Sumerel; Yifei Ma; Mark E Scott
Journal:  Clin Vaccine Immunol       Date:  2007-10-31

Review 5.  Comprehensive control of human papillomavirus infections and related diseases.

Authors:  F Xavier Bosch; Thomas R Broker; David Forman; Anna-Barbara Moscicki; Maura L Gillison; John Doorbar; Peter L Stern; Margaret Stanley; Marc Arbyn; Mario Poljak; Jack Cuzick; Philip E Castle; John T Schiller; Lauri E Markowitz; William A Fisher; Karen Canfell; Lynette A Denny; Eduardo L Franco; Marc Steben; Mark A Kane; Mark Schiffman; Chris J L M Meijer; Rengaswamy Sankaranarayanan; Xavier Castellsagué; Jane J Kim; Maria Brotons; Laia Alemany; Ginesa Albero; Mireia Diaz; Silvia de Sanjosé
Journal:  Vaccine       Date:  2013-12-30       Impact factor: 3.641

6.  Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.

Authors:  Anna Paaso; Hanna-Mari Koskimaa; Marij Jp Welters; Seija Grénman; Kari Syrjänen; Sjoerd H van der Burg; Stina Syrjänen
Journal:  J Transl Med       Date:  2015-05-20       Impact factor: 5.531

7.  Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients.

Authors:  Tae Jin Kim; Hyun-Tak Jin; Soo-Young Hur; Hyun Gul Yang; Yong Bok Seo; Sung Ran Hong; Chang-Woo Lee; Suhyeon Kim; Jung-Won Woo; Ki Seok Park; Youn-Young Hwang; Jaehan Park; In-Ho Lee; Kyung-Taek Lim; Ki-Heon Lee; Mi Seon Jeong; Charles D Surh; You Suk Suh; Jong Sup Park; Young Chul Sung
Journal:  Nat Commun       Date:  2014-10-30       Impact factor: 14.919

8.  Effects of Th17 cells and IL-17 in the progression of cervical carcinogenesis with high-risk human papillomavirus infection.

Authors:  JiSen Xue; YuLi Wang; Cheng Chen; XueJie Zhu; Hua Zhu; Yan Hu
Journal:  Cancer Med       Date:  2017-12-26       Impact factor: 4.452

9.  Production of interleukin‑4 in CD133+ cervical cancer stem cells promotes resistance to apoptosis and initiates tumor growth.

Authors:  Chun-Tao Liu; Ying Xin; Chun-Yan Tong; Bing Li; Hong-Li Bao; Cai-Yun Zhang; Xue-Hui Wang
Journal:  Mol Med Rep       Date:  2016-04-27       Impact factor: 2.952

10.  Candidate Soluble Immune Mediators in Young Women with High-Risk Human Papillomavirus Infection: High Expression of Chemokines Promoting Angiogenesis and Cell Proliferation.

Authors:  Nunzia Zanotta; Maria Lina Tornesello; Clorinda Annunziata; Giovanni Stellato; Franco Maria Buonaguro; Manola Comar
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

View more
  3 in total

1.  IL-6 and IL-10 Are Associated With Gram-Negative and Gram-Positive Bacteria Infection in Lymphoma.

Authors:  Qiuhua Zhu; Huan Li; Shanshan Zheng; Bin Wang; Mingjie Li; Wenbin Zeng; Lanlan Zhou; Zebing Guan; Hong Wang; Yanan Liu; Yanmin Gao; Shiqiu Qiu; Chaolun Chen; Shimei Yang; Yuemei Yuan; Hanling Zhang; Guanqiao Ruan; Xueyi Pan
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 7.561

2.  High Expression of Circular RNA-Mitochondrial tRNA Translation Optimization 1 Assists the Diagnosis of High-Risk Human Papillomavirus Infection in Cervical Cancer.

Authors:  Xiyun Cheng; Changmei Shen; Zhenrong Liao
Journal:  J Low Genit Tract Dis       Date:  2022-05-14       Impact factor: 3.842

Review 3.  Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite.

Authors:  Johannes Huber; Anna Mueller; Manuela Sailer; Pedro-Antonio Regidor
Journal:  Womens Health (Lond)       Date:  2021 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.